Ziopharm Oncology Inc. (ZIOP) Lowered to “Hold” at Zacks Investment Research
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
ZIOP has been the topic of a number of other reports. Wells Fargo & Co. raised Ziopharm Oncology from an underperform rating to a market perform rating in a report on Wednesday, August 10th. Griffin Securities reaffirmed a buy rating and issued a $21.00 price objective on shares of Ziopharm Oncology in a report on Monday, August 15th. Finally, Mizuho reaffirmed a neutral rating and issued a $5.00 price objective (down from $7.00) on shares of Ziopharm Oncology in a report on Monday, July 18th. Five research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $9.75.
Shares of Ziopharm Oncology (NASDAQ:ZIOP) traded down 0.57% during mid-day trading on Wednesday, reaching $5.21. The company had a trading volume of 215,482 shares. The company’s market cap is $679.88 million. Ziopharm Oncology has a 52-week low of $4.45 and a 52-week high of $14.93. The firm’s 50-day moving average price is $5.44 and its 200 day moving average price is $6.29.
Ziopharm Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.90. Ziopharm Oncology had a negative net margin of 2,292.26% and a negative return on equity of 100.01%. The firm earned $1.70 million during the quarter, compared to analyst estimates of $1.52 million. During the same period in the prior year, the company earned ($0.11) earnings per share. The business’s quarterly revenue was up 525.0% compared to the same quarter last year. Equities analysts expect that Ziopharm Oncology will post ($1.34) EPS for the current year.
Institutional investors have recently modified their holdings of the company. Advisor Group Inc. purchased a new position in shares of Ziopharm Oncology during the second quarter worth about $105,000. Royal Bank of Canada boosted its stake in shares of Ziopharm Oncology by 18.8% in the second quarter. Royal Bank of Canada now owns 19,235 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 3,046 shares during the last quarter. Oppenheimer & Co. Inc. boosted its stake in shares of Ziopharm Oncology by 4.8% in the second quarter. Oppenheimer & Co. Inc. now owns 20,100 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 919 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Ziopharm Oncology during the second quarter valued at $114,000. Finally, Principal Financial Group Inc. boosted its stake in shares of Ziopharm Oncology by 5.5% in the second quarter. Principal Financial Group Inc. now owns 21,388 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 1,124 shares during the last quarter. 44.94% of the stock is owned by institutional investors and hedge funds.
Ziopharm Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.
Receive News & Stock Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related stocks with our FREE daily email newsletter.